Janice Pogue

List of Articles by Year in descending order

Source: //exaly.com/author-pdf/10852260/publications.pdf

Version: 2025-02-01

90 peer-reviewed articles	32,801 peer-reviewed citations	31060 54 peer-reviewed h-index	92367 6.25 score
97 documents	39659 doc citations	35916 56 h-index	52862 citing authors

#	Article	IF	Citations
1	Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study. Anesthesia and Analgesia, 2017, 125, 162-169.	1.5	43
2	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European Stroke Journal, 2016, 1, 146-154.	2.8	91
3	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	26.4	580
4	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	26.4	772
5	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	26.4	347
6	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. Canadian Journal of Cardiology, 2016, 32, 1332-1339.	1.4	10
7	Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 244-253.	12.4	111
8	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace, 2016, 18, 973-978.	1.8	19
9	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	1.4	28
10	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2015, 132, 796-803.	13.1	114
11	Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 1243-1253.	46.9	347
12	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. Circulation, 2015, 132, 2297-2304.	13.1	69
13	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney International, 2015, 87, 784-791.	4.2	114
14	Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease. Hypertension, 2015, 65, 108-114.	4.7	78
15	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. Heart Rhythm, 2014, 11, 2156-2162.	1.9	30
16	Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study". Circulation, 2014, 130, .	13.1	4
17	Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. European Heart Journal, 2014, 35, 1743-1751.	2.6	27
18	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). American Journal of Cardiology, 2014, 113, 669-675.	1.5	16

#	Article	IF	Citations
19	Clonidine in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine, 2014, 370, 1504-1513.	26.4	349
20	The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. Journal of Clinical Epidemiology, 2014, 67, 622-628.	2.5	734
21	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128, 237-243.	13.1	200
22	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation, 2013, 128, 2192-2201.	13.1	302
23	Nitrous Oxide and Serious Morbidity and Mortality in the POISE Trial. Anesthesia and Analgesia, 2013, 116, 1034-1040.	1.5	36
24	Cardiovascular Risk in Patients with Early Renal Insufficiency. American Journal of Cardiovascular Drugs, 2012, 2, 157-162.	1.9	10
25	Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Critical Care, 2012, 16, .	4.1	289
26	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	26.4	1,545
27	Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes. PLoS ONE, 2012, 7, e34785.	1.5	47
28	Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery. Annals of Internal Medicine, 2011, 154, 523-528.	7.3	623
29	Irbesartan in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 928-938.	26.4	239
30	Testing for heterogeneity among the components of a binary composite outcome in a clinical trial. BMC Medical Research Methodology, 2010, 10, .	1.7	24
31	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. JAMA - Journal of the American Medical Association, 2010, 304, 1339-1349.	14.4	180
32	Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation. Circulation, 2010, 122, 2246-2253.	13.1	159
33	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. European Heart Journal, 2010, 31, 2133-2140.	2.6	35
34	Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 277-283.	2.8	102
35	Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation acute coronary syndromes initially treated with fondaparinux. American Heart Journal, 2010, 160, 1029-1034.e1.	1.8	21
36	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, The, 2010, 376, 975-983.	46.9	948

#	Article	IF	Citations
37	Referrals in Acute Coronary Events for CARdiac Catheterization: The RACE CAR trial. Canadian Journal of Cardiology, 2010, 26, e290-e296.	1.4	9
38	Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009, 360, 2066-2078.	26.4	1,333
39	The Family Atherosclerosis Monitoring In earLY life (FAMILY) study. American Heart Journal, 2009, 158, 533-539.	1.8	57
40	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009, 361, 1139-1151.	26.4	10,698
41	Effect of Telmisartan on Renal Outcomes. Annals of Internal Medicine, 2009, 151, 1-10.	7.3	172
42	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine, 2008, 358, 1547-1559.	26.4	3,384
43	Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet, The, 2008, 371, 1839-1847.	46.9	2,185
44	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet, The, 2008, 372, 547-553.	46.9	1,500
45	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet, The, 2008, 372, 1174-1183.	46.9	948
46	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal, 2008, 30, 900-907.	2.6	121
47	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation, 2008, 118, 2029-2037.	13.1	828
48	Response to Letter Regarding Article, “Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation”. Circulation, 2008, 117, .	13.1	0
49	The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. Nature Clinical Practice Cardiovascular Medicine, 2008, 6, 96-97.	0.0	15
50	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. Circulation, 2007, 116, 449-455.	13.1	83
51	Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. European Heart Journal, 2007, 28, 1382-1388.	2.6	31
52	Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. European Heart Journal, 2007, 28, 850-856.	2.6	922
53	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. Journal of the American College of Cardiology, 2007, 50, 2156-2161.	0.7	448
54	Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, The, 2006, 367, 1903-1912.	46.9	1,895

#	Article	IF	Citations
55	Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet, The, 2006, 368, 581-588.	46.9	478
56	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine, 2006, 354, 1464-1476.	26.4	1,164
57	Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. New England Journal of Medicine, 2006, 354, 1567-1577.	26.4	1,651
58	Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction. American Journal of Cardiology, 2006, 98, 758-760.	1.5	10
59	Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. American Journal of Kidney Diseases, 2006, 48, 889-896.	1.0	28
60	Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta-analysis. European Journal of Heart Failure, 2006, 8, 90-96.	5.0	26
61	The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 2005, 48, 1749-1755.	4.9	241
62	ACE Inhibition in Stable Coronary Artery Disease. New England Journal of Medicine, 2005, 352, 937-939.	26.4	45
63	Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. Circulation, 2005, 112, 1339-1346.	13.1	175
64	Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. American Heart Journal, 2005, 149, 54-60.	1.8	309
65	Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. Circulation, 2004, 110, 1413-1417.	13.1	63
66	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International, 2004, 65, 1375-1380.	4.2	110
67	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia, 2004, 47, 1519-1527.	4.9	160
68	Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal, 2004, 148, 52-61.	1.8	393
69	Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 420-428.	2.2	25
70	Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2003, 107, 1284-1290.	13.1	212
71	Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2003, 107, 960-965.	13.1	60
72	Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin. Circulation, 2003, 107, 2884-2888.	13.1	103

#	Article	IF	Citations
73	Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. European Heart Journal, 2002, 23, 117-123.	2.6	26
74	Use of ramipril in preventing stroke: double blind randomised trial. BMJ: British Medical Journal, 2002, 324, 699-699.	0.1	368
75	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet, The, 2002, 360, 1037-1043.	46.9	230
76	Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet, The, 2001, 358, 2130-2131.	46.9	228
77	Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. Annals of Internal Medicine, 2001, 134, 629-636.	7.3	1,274
78	Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials. JAMA - Journal of the American Medical Association, 2001, 285, 444.	14.4	30
79	Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. New England Journal of Medicine, 2000, 342, 154-160.	26.4	1,918
80	Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet, The, 2000, 355, 1575-1581.	46.9	1,471
81	Functional capacity in patients with congestive heart failure. Journal of Cardiac Failure, 2000, 6, 214-219.	0.9	30
82	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. Journal of the American College of Cardiology, 1999, 33, 612-619.	0.7	94
83	Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet, The, 1998, 351, 47-52.	46.9	427
84	Elevated lipoprotein(a) levels in South Asians in North America. Metabolism: Clinical and Experimental, 1998, 47, 182-184.	8.9	92
85	Primary Angioplasty Compared With Thrombolytic Therapy for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 1997, 278, 2110.	14.4	18
86	Study Design and Baseline Characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE**This study was supported by Research Grant UI-12363 from the Medicine Research Council of Canada, Ottawa; and by Hoechst Marion Roussel, Laval, Canada, Inc.. American Journal of Cardiology, 1996, 78, 914-919.	1.5	35
87	Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. Diabetes Care, 1996, 19, 1225-1228.	5.6	69
88	63A Utilizing sequential monitoring boundaries for cumulative meta-analysis. Contemporary Clinical Trials, 1995, 16, 69S.	2.8	1
89	P300 latency indexes nitrogen narcosis. Electroencephalography and Clinical Neurophysiology, 1990, 75, 221-229.	2.4	11
90	Weighted Multiple Testing Correction for Correlated Binary Endpoints. Communications in Statistics Part B: Simulation and Computation, 0, 42, 1693-1702.	0.8	0